蕈狀肉芽腫（MF）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國中型股（MF）市場預計將從2025年的1,400萬美元成長到2035年的2,600萬美元。
• 推動市場成長的因素如下：
• 標靶治療和生物製藥的應用日益增多
• 擴大皮膚T細胞淋巴瘤的臨床研究
• 未來的成長將取決於能夠提供更高安全性和持續疾病控制的療法。

蕈狀肉芽腫（MF）概述

蕈狀肉芽腫（MF）是最常見的原發性皮膚T細胞淋巴瘤，由CD4陽性記憶T細胞在皮膚中聚集並發生剋隆性增生所致。其臨床病程通常緩慢進展，經歷斑塊、斑塊和腫瘤三個特徵階段，晚期病變可擴散至淋巴結、血液和內臟器官。診斷包括對臨床形態學、皮膚切片檢查（顯示表皮親和性異型性淋巴細胞）、免疫組織化學以及T細胞受體克隆性檢測的全面評估。早期病例可透過皮膚定向治療（如局部皮質類固醇、氮芥、照光治療和局部放射線治療）進行有效控制。對於復發或難治性系統性疾病，標靶治療是治療的核心。第一線系統治療包括用於CD30陽性疾病的維布妥昔單抗、靶向CCR4的抗體mogamulizumab以及口服retinoid bexarotene。尤其值得關注的是，針對白細胞介素Lymphir（denileukin diftitox-cxdl）的獲批，該藥已獲批用於治療初始全身治療失敗後的1-3期疾病，拓寬了治療選擇。其他全身性治療方案包括組蛋白去乙醯化酶抑制劑，例如romidepsin和 vorinostat，以及低劑量胺基甲基葉酸。皮膚科醫生和血液科醫生的多學科後續觀察對於最大限度地提高患者生存率和維持其生活品質仍然非常重要。

主要亮點

• 根據預測，德國蕈狀肉芽腫（MF）新病例數將從2025年的525 例增加到2035年的552 例。
• MF是皮膚T細胞淋巴瘤中最常見的一種，其特徵是病程呈慢性進行性。
• 晚期疾病診斷延遲和治療選擇有限仍然是主要的臨床挑戰。
• 目前仍有大量未被滿足的需求，即缺乏能夠提供持續療效並改善長期結果的治療方法。

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

提及公司

• Virogen Biotechnology Inc.
• Soligenix
• SciTech Development, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Mycosis Fungoides (MF) Market Outlook

Thelansis's "Mycosis Fungoides (MF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mycosis Fungoides treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Mycosis Fungoides (MF) Overview

Mycosis fungoides is the most common primary cutaneous T-cell lymphoma, arising from the clonal proliferation of skin-homing CD4-positive memory T-cells. It typically follows an indolent clinical course through distinct patch, plaque, and tumor stages, with advanced disease tracking to lymph nodes, blood, and visceral organs. Diagnosis integrates clinical morphology, skin biopsy showing epidermotropic atypical lymphocytes, immunohistochemistry, and T-cell receptor clonality studies. Skin-directed therapies like topical corticosteroids, nitrogen mustard, phototherapy, and localized radiation successfully manage early-stage presentations. For relapsed or refractory systemic disease, the therapeutic landscape centers on targeted approaches. First-line systemic protocols include brentuximab vedotin for CD30-positive disease, the CCR4-directed antibody mogamulizumab, and the oral retinoid bexarotene. Crucially, the management toolkit has expanded with the approval of Lymphir (denileukin diftitox-cxdl), an interleukin-2 receptor-targeted immunotherapy indicated for stage 1 to 3 disease following initial systemic failure. Other systemic options include histone deacetylase inhibitors like romidepsin and vorinostat, alongside low-dose methotrexate. Multidisciplinary dermatological and hematological monitoring remains essential to maximize life expectancy and preserve patient quality of life.

Key Highlights

• In Germany, incident Mycosis Fungoides (MF) cases are projected to increase from 525 in 2025 to 552 by 2035.
• MF is the most common form of cutaneous T-cell lymphoma, characterized by a chronic and progressive disease course.
• Delayed diagnosis and limited treatment options for advanced disease remain key clinical challenges.
• Significant unmet need persists for therapies that provide durable responses and improve long-term outcomes.

Market Overview

• The France MF market is projected to grow from $14M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted and biologic therapies
• Growing clinical research in cutaneous T-cell lymphoma
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Virogen Biotechnology Inc.
• Soligenix
• SciTech Development, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)